Thalidomide suppresses inflammation in adenine-induced CKD with uraemia in mice

Nephrology Dialysis Transplantation

Volumn 28, Issue 5, 2013, Pages 1140-1149

  Santana, Alexandre C ^a   Degaspari, Sabrina ^a   Catanozi, Sergio ^a   Dellê, Humberto ^a   De Sá Lima, Larissa ^a   Silva, Cleonice ^a   Blanco, Paula ^b   Solez, Kim ^b   Scavone, Cristoforo ^a   Noronha, Irene L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

adenine; chronic kidney disease; inflammation; thalidomide

Indexed keywords

ADENINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; PARATHYROID HORMONE; PHOSPHORUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FOOD INTAKE; GEL MOBILITY SHIFT ASSAY; HISTOPATHOLOGY; IMMUNOMODULATION; INFLAMMATION; MALE; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; UREMIA; URINE VOLUME;

ADENINE; CHRONIC KIDNEY DISEASE; INFLAMMATION; THALIDOMIDE;

ADENINE; ANIMALS; BLOTTING, WESTERN; CYTOKINES; DISEASE MODELS, ANIMAL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; RENAL INSUFFICIENCY, CHRONIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THALIDOMIDE; UREMIA;

EID: 84877972647     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs569     Document Type: Article

References (36)

1. Couser WG, Remuzzi G, Mendis S et al. The contribution of chronic kidney disease to the global burden of major noncom-municable diseases. Kidney Int 2011; 12: 1258-1270
2. Amore A, Coppo R. Immunological basis of inflammation in dialysis. Nephrol Dial Transplant 2002; 17: 16-24
3. Stenvinkel P, Ketteler M, Johnson RJ et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia- the good, the bad, and the ugly. Kidney Int 2005; 67: 1216-1233
4. Rysz J, Banach M, Cialkowska-Rysz A et al. Blood serum levels of IL-2, IL-6, IL-8, TNF-alpha and IL-1beta in patients on maintenance hemodialysis. Cell Mol Immunol 2006; 3: 151-154
5. Oberg BP, McMenamin E, Lucas FL et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 3: 1009-1016
6. Raje N, Anderson K. Thalidomide-a revival story. N Engl J Med 1999; 18: 1565-1571
7. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 18: 1565-1571
8. Huang F, Gu J, Zhao W et al. One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum 2002; 47: 249-254
9. Tramontana JM, Utaipat U, Molloy A et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995; 1: 384-397
10. Wohl DA, Aweeka FT, Schmitz J et al. Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267. J Infect Dis 2002; 185: 1359-1363
11. Teo SK, Colburn WA, Tracewell WG et al. Clinical pharmacoki-netics of thalidomide. Clin Pharmacokinet 2004; 43: 311-327
12. Yokozawa T, Zheng PD, Oura H et al. Animal model of adenine-induced chronic renal failure in rats. Nephron 1986; 44: 230-234
13. Ataka K, Maruyama H, Neichi T et al. Effects of erythropoietin-gene electrotransfer in rats with adenine-induced renal failure. Am J Nephrol 2003; 5: 315-323
14. Tamagaki K, Yuan Q, Ohkawa H et al. Severe hyperparathyroid-ism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. Nephrol Dial Transplant 2006; 21: 651-659
15. Matsui I, Hamano T, Mikami S et al. Fully phosphorylated fetuin-A forms a mineral complex in the serum of rats with adenine-induced renal feilure. Kidney Int 2009; 75: 915-928
16. Tamura M, Aizawa R, Hori M et al. Progressive renal dysfunction and macrophage infiltration in interstitial fibrosis in an adenine-induced tubulointerstitial nephritis mouse model. Histochem Cell Biol 2009; 131: 483-490
17. Tanaka T, Doi K, Maeda-Mamiya R et al. Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury. Am J Pathol 2009; 174: 1203-1211
18. Arruda MS, Richini VB, Oliveira SM et al. Experimental murine mycobacteriosis: evaluation of the functional activity of alveolar macrophages in thalidomide-treated mice. Braz J Med Biol Res 2004; 37: 485-492
19. Solgi G, Kariminia A, Abdi K et al. Effects of combined therapy with thalidomide and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice. Korean J Parasitol 2006; 44: 55-61
20. Dellê H, Rocha JR, Cavaglieri RC et al. Antifibrotic effect of ta-moxifen in a model of progressive renal disease. J Am Soc Nephrol 2012; 23: 37-48
21. Nishio Y, Kashiwagi A, Taki H et al. Altered activities of transcription factors and their related gene expression in cardiac tissues of diabetic rats. Diabetes 1998; 47: 1318-1325
22. Glezer I, Munhoz CD, Kawamoto EM et al. MK-801 and 7-Ni attenuate the activation of brain NF-kappa B induced by LPS. Neuropharmacology 2003; 45: 1120-1129
23. Nogueira AC, Neubert R, Felies A et al. Thalidomide derivatives and the immune system. 6. Effects of two derivatives with no obvious teratogenic potency on the pattern of integrins and other surface receptors on blood cells of marmosets. Life Sci 1996; 58: 337-348
24. Corral LG, Haslett PA, Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999; 163: 380-386
25. Fujita J, Mestre JR, Zeldis JB et al. Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygen-ase-2. Clin Cancer Res 2001; 7: 3349-3355
26. Ikeda R, Imai Y, Maruyama W et al. Systemic disorders of calcium dynamics in rats with adenine-induced renal failure: implication for chronic kidney disease-related complications. Ne-phrology (Carlton) 2010; 15: 54-62
27. Lavi-Moshayoff V, Wasserman G, Meir T et al. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010; 299: 882-889
28. Pecoits-Filho R, Bárány P, Lindholm B et al. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17: 1684-1688
29. Sampaio EP, Sarno EN, Galilly R et al. Thalidomide selectively inhibits tumor necrosis factor-α production by stimulated human monocytes. J Exp Med 1991; 173: 699-703
30. Moreira AL, Sampaio EP, Zmuidzinas A et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-1680
31. Moreira AL, Wang J, Sarno EN et al. Thalidomide protects mice against LPS-induced shock. Braz J Med Biol Res 1997; 30: 1199-11207
32. Sampaio EP, Kaplan G, Miranda A et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993; 168: 408-514
33. Keifer JA, Guttridge DC, Ashburner BP et al. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001; 276: 22382-22387
34. 2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol 2002; 168: 2644-2651
35. Yagyu T, Kobayashi H, Matsuzaki H et al. Thalidomide inhibits tumor necrosis factor-α-induced interleukin-8 expression in endometriotic stromal cells, possibly through suppression of nuclear factor-kB activation. J Clin Endocrinol Metab 2005; 90: 3017-3021
36. Bringhen S, Gay F, Pautasso C et al. Evaluation of the pharmaco-kinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. Expert Opin Drug Metab Toxicol 2012; 8: 1209-1222